This is a working overview of immunomodulator, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-11 and is reviewed periodically as new material appears.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual description varies by batch |
| Solubility | Freely soluble in water | Aqueous buffers are commonly used |
| Typical storage temperature | -20 °C or below for powder | Reconstituted liquid kept at 2-8 °C short term |
| Purity method | Reversed-phase HPLC | Value derived from peak area integration |
| Identity method | Mass spectrometry | Confirms mass and sequence integrity |
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Avoiding the use of bisphosphonates is not a viable preventive strategy on a general-population basis because the medications are beneficial in the treatment and prevention of osteoporosis (including prevention of bony fractures) and treatment of bone cancers. Current recommendations are for a 2-month drug holiday prior to dental surgery for those who are at risk (intravenous drug therapy, greater than 4 years of by-mouth drug therapy, other factors that increase risk such as steroid therapy). It usually develops after dental treatments involving exposure of bone or trauma, but may arise spontaneously. Patients who develop MRONJ may experience prolonged healing, pain, swelling, infection and exposed bone after dental procedures, though some patients may have no signs/symptoms.
== Applications == Food-packaging applications include oxygen removal, moisture control, ethylene scavenging, antimicrobial activity, modified-atmosphere maintenance, freshness indication, and temperature monitoring. Pharmaceutical and medical applications include moisture-control closures, oxygen absorbers, temperature indicators, authentication features, adherence monitoring, and track-and-trace systems. Industrial applications include corrosion-inhibiting packaging for machinery, electronics, tools, automotive components, and military equipment. Shock and vibration monitoring is used with calibrated or fragile products. Agricultural applications include ethylene-control materials, humidity management, antimicrobial pads, freshness indicators, and controlled-release substances used during produce storage and distribution. Active packaging can also be used in transport systems for biological materials and organs, although these applications require specialised temperature control, sterility, and regulatory oversight.
The ribbons' conductance exceeds predictions by a factor of 10. The ribbons can function more like optical waveguides or quantum dots, allowing electrons to flow smoothly along the ribbon edges. In copper, resistance increases proportionally with length as electrons encounter impurities. Transport is dominated by two modes: one ballistic and temperature-independent, and the other thermally activated. Ballistic electrons resemble those in cylindrical carbon nanotubes. At room temperature, resistance increases abruptly at a specific length—the ballistic mode at 16 micrometers and the thermally activated mode at 160 nanometers (1% of the former length). Graphene electrons can traverse micrometer distances without scattering, even at room temperature.
These failures suggested that either these are the wrong molecular targets to induce neovascularization, that they can only be effectively used if formulated and administered correctly, or that their presentation in the context of the overall cellular microenvironment may play a vital role in their utility. It may be necessary to present these proteins in a way that mimics natural signaling events, including the concentration, spatial and temporal profiles, and their simultaneous or sequential presentation with other appropriate factors.
== Analysis == The chemical analysis of fatty acids in lipids typically begins with an interesterification step that breaks down their original esters (triglycerides, waxes, phospholipids etc.) and converts them to methyl esters, which are then separated by gas chromatography or analyzed by gas chromatography and mid-infrared spectroscopy. Separation of unsaturated isomers is possible by silver ion complemented thin-layer chromatography. Other separation techniques include high-performance liquid chromatography (with short columns packed with silica gel with bonded phenylsulfonic acid groups whose hydrogen atoms have been exchanged for silver ions). The role of silver lies in its ability to form complexes with unsaturated compounds.
Sources: en.wikipedia.org
Related to its ability to dissolve many salts, DMSO is a common ligand in coordination chemistry. Illustrative is the complex dichlorotetrakis(dimethyl sulfoxide)ruthenium(II) (RuCl2(dmso)4). In this complex, three DMSO ligands are bonded to ruthenium through sulfur. The fourth DMSO is bonded through oxygen. In general, the oxygen-bonded mode is more common. In carbon tetrachloride solutions DMSO functions as a Lewis base with a variety of Lewis acids such as I2, phenols, trimethyltin chloride, metalloporphyrins, and the dimer Rh2Cl2(CO)4. The donor properties are discussed in the ECW model. The relative donor strength of DMSO toward a series of acids, versus other Lewis bases, can be illustrated by C-B plots.
=== EC 2.6.1: Transaminases === EC 2.6.1.1: aspartate transaminase EC 2.6.1.2: alanine transaminase EC 2.6.1.3: cysteine transaminase EC 2.6.1.4: glycine transaminase EC 2.6.1.5: tyrosine transaminase EC 2.6.1.6: leucine transaminase EC 2.6.1.7: kynurenine—oxoglutarate transaminase EC 2.6.1.8: deleted EC 2.6.1.9: histidinol-phosphate transaminase EC 2.6.1.10: deleted, included with EC 2.6.1.21, D-amino-acid transaminase EC 2.6.1.11: acetylornithine transaminase EC 2.6.1.12: alanine—oxo-acid transaminase EC 2.6.1.13: ornithine aminotransferase EC 2.6.1.14: asparagine—oxo-acid transaminase EC 2.6.1.15: glutamine—pyruvate transaminase EC 2.6.1.16: glutamine—fructose-6-phosphate transaminase (isomerizing) EC 2.6.1.17: succinyldiaminopimelate transaminase EC 2.6.1.18: β-alanine—pyruvate transaminase EC 2.6.1.19: 4-aminobutyrate transaminase EC 2.6.1.20: deleted EC 2.6.1.21: D-amino-acid transaminase EC 2.6.1.22: (S)-3-amino-2-methylpropionate transaminase EC 2.6.1.23: 4-hydroxyglutamate transaminase EC 2.6.1.24: diiodotyrosine transaminase EC 2.6.1.25: deleted, Now included with EC 2.6.1.24 diiodotyrosine transaminase EC 2.6.1.26: thyroid-hormone transaminase EC 2.6.1.27: tryptophan transaminase EC 2.6.1.28: tryptophan—phenylpyruvate transaminase EC 2.6.1.29: diamine transaminase EC 2.6.1.30: pyridoxamine—pyruvate transaminase EC 2.6.1.31: pyridoxamine—oxaloacetate transaminase EC 2.6.1.32: valine—3-methyl-2-oxovalerate transaminase EC 2.6.1.33: dTDP-4-amino-4,6-dideoxy-D-glucose transaminase EC 2.6.1.34: UDP-N-acetylbacillosamine transaminase EC 2.6.1.35: glycine—oxaloacetate transaminase EC 2.6.1.36: L-lysine 6-transaminase EC 2.6.1.37: (2-aminoethyl)phosphonate—pyruvate transaminase EC 2.6.1.38: histidine transaminase EC 2.6.1.39: 2-aminoadipate transaminase EC 2.6.1.40: (R)-3-amino-2-methylpropionate—pyruvate transaminase EC 2.6.1.41: D-methionine—pyruvate transaminase EC 2.6.1.42: branched-chain-amino-acid transaminase EC 2.6.1.43: aminolevulinate transaminase EC 2.6.1.44: alanine—glyoxylate transaminase EC 2.6.1.45: serine—glyoxylate transaminase EC 2.6.1.46: diaminobutyrate—pyruvate transaminase EC 2.6.1.47: alanine—oxomalonate transaminase EC 2.6.1.48: 5-aminovalerate transaminase EC 2.6.1.49: dihydroxyphenylalanine transaminase EC 2.6.1.50: glutamine—scyllo-inositol transaminase EC 2.6.1.51: serine—pyruvate transaminase EC 2.6.1.52: phosphoserine transaminase EC 2.6.1.53: Now EC 1.4.1.13, glutamate synthase (NADPH) EC 2.6.1.54: pyridoxamine-phosphate transaminase EC 2.6.1.55: taurine—2-oxoglutarate transaminase EC 2.6.1.56: 1D-1-guanidino-3-amino-1,3-dideoxy-scyllo-inositol transaminase EC 2.6.1.57: aromatic-amino-acid transaminase EC 2.6.1.58: phenylalanine(histidine) transaminase EC 2.6.1.59: dTDP-4-amino-4,6-dideoxygalactose transaminase EC 2.6.1.60: aromatic-amino-acid—glyoxylate transaminase EC 2.6.1.61: identical to EC 2.6.1.40, (R)-3-amino-2-methylpropionate—pyruvate transaminase EC 2.6.1.62: adenosylmethionine—8-amino-7-oxononanoate transaminase EC 2.6.1.63: kynurenine—glyoxylate transaminase EC 2.6.1.64: glutamine—phenylpyruvate transaminase EC 2.6.1.65: N6-acetyl-β-lysine transaminase EC 2.6.1.66: valine—pyruvate transaminase EC 2.6.1.67: 2-aminohexanoate transaminase EC 2.6.1.68: Now classified as EC 2.6.1.13, ornithine aminotransferase and EC 2.6.1.36, L-lysine 6-transaminase EC 2.6.1.69: identical to EC 2.6.1.11, ((acetylornithine transaminase))|identical to EC 2.6.1.11, acetylornithine transaminase EC 2.6.1.70: aspartate—phenylpyruvate transaminase EC 2.6.1.71: lysine—pyruvate 6-transaminase EC 2.6.1.72: D-4-hydroxyphenylglycine transaminase EC 2.6.1.73: methionine—glyoxylate transaminase EC 2.6.1.74: cephalosporin-C transaminase EC 2.6.1.75: cysteine-conjugate transaminase EC 2.6.1.76: diaminobutyrate—2-oxoglutarate transaminase EC 2.6.1.77: taurine—pyruvate aminotransferase EC 2.6.1.78: aspartate—prephenate aminotransferase EC 2.6.1.79: glutamate—prephenate aminotransferase EC 2.6.1.80: nicotianamine aminotransferase EC 2.6.1.81: succinylornithine transaminase EC 2.6.1.82: putrescine aminotransferase EC 2.6.1.83: LL-diaminopimelate aminotransferase EC 2.6.1.84: arginine—pyruvate transaminase EC 2.6.1.85: aminodeoxychorismate synthase EC 2.6.1.86: 2-amino-4-deoxychorismate synthase EC 2.6.1.87: UDP-4-amino-4-deoxy-L-arabinose aminotransferase EC 2.6.1.88: methionine transaminase EC 2.6.1.89: dTDP-3-amino-3,6-dideoxy-α-D-glucopyranose transaminase EC 2.6.1.90: dTDP-3-amino-3,6-dideoxy-α-D-galactopyranose transaminase EC 2.6.1.91: Identical to EC 2.6.1.34, UDP-N-acetylbacillosamine transaminase EC 2.6.1.92: UDP-4-amino-4,6-dideoxy-N-acetyl-β-L-altrosamine transaminase EC 2.6.1.93: neamine transaminase EC 2.6.1.94: 2′-deamino-2′-hydroxyneamine transaminase EC 2.6.1.95: neomycin C transaminase EC 2.6.1.96: 4-aminobutyrate—pyruvate transaminase EC 2.6.1.97: archaeosine synthase EC 2.6.1.98: UDP-2-acetamido-2-deoxy-ribo-hexuluronate aminotransferase EC 2.6.1.99: L-tryptophan—pyruvate aminotransferase EC 2.6.1.100: L-glutamine:2-deoxy-scyllo-inosose aminotransferase EC 2.6.1.101: L-glutamine:3-amino-2,3-dideoxy-scyllo-inosose aminotransferase EC 2.6.1.102: GDP-perosamine synthase EC 2.6.1.103: (S)-3,5-dihydroxyphenylglycine transaminase EC 2.6.1.104: 3-dehydro-glucose-6-phosphate—glutamate transaminase EC 2.6.1.105: lysine—8-amino-7-oxononanoate transaminase EC 2.6.1.106: dTDP-3-amino-3,4,6-trideoxy-α-D-glucose transaminase EC 2.6.1.107: β-methylphenylalanine transaminase EC 2.6.1.108: (5-formylfuran-3-yl)methyl phosphate transaminase EC 2.6.1.109: 8-amino-3,8-dideoxy-α-D-manno-octulosonate transaminase EC 2.6.1.110: dTDP-4-dehydro-2,3,6-trideoxy-D-glucose 4-aminotransferase EC 2.6.1.111: 3-aminobutanoyl-CoA transaminase EC 2.6.1.112: (S)-ureidoglycine—glyoxylate transaminase EC 2.6.1.113: putrescine—pyruvate transaminase EC 2.6.1.114: 8-demethyl-8-aminoriboflavin-5′-phosphate synthase EC 2.6.1.115: 5-hydroxydodecatetraenal 1-aminotransferase EC 2.6.1.116: 6-aminohexanoate aminotransferase EC 2.6.1.117: L-glutamine—4-(methylsulfanyl)-2-oxobutanoate aminotransferase EC 2.6.1.118: [amino-group carrier protein]-γ-(L-lysyl)-L-glutamate aminotransferase EC 2.6.1.119: vanillin aminotransferase
=== Cordelia Hanani-Spyrka === Cordelia Hanani-Spyrka (Claire Forlani) is Yasmin's aunt and the sister of her late father Charles, working as a public relations executive. Yasmin invites her to Henry's 40th birthday, where Cordelia gushes about her relationship with a younger man, and advises Yasmin not to tie her future to Henry, warning that men invariably weaponize women's unconditional love. Yasmin later catches Cordelia performing oral sex on Otto Mostyn and confronts her afterwards, asking why she never came to Charles' funeral and whether she knew about his serial sexual predation; Cordelia dismisses her brother's behavior, arguing that both she and Charles came from a "bohemian childhood", and it is implied the two had an incestuous relationship in their youth. Before leaving, Cordelia spitefully tells Yasmin that Charles planned to terminate her before learning she would be born a girl.
As mayor of Nuevo Cuscatlán, Bukele described himself as part of the "radical left" because he wanted "radical changes" ("cambios radicales") for El Salvador; he also stated that his family had always had significant connections with the Salvadoran political left. Bukele believed in social justice and the state obligation to guarantee Salvadorans the opportunity for "health, education, [and] productive infrastructure" ("salud, educación, [e] infraestructura productiva"). Some FMLN members criticized Bukele's work as a businessman, believing that it contradicted the "historic goal of the proletariat" ("papel histórico del proletariado"): eliminating capitalism. Since becoming president, Bukele has stated that he does not adhere to any specific political ideology. He has criticized the political left and right in El Salvador for dividing the country after the civil war. In an interview with Time's Vera Bergengruen, he stated that he did not consider himself either left- or right-wing. El Faro's editorial board has described Bukele as a "politician without an ideology" ("político sin ideología"). Despite Bukele's ostensible ideologic neutrality, some journalists and political analysts have described him as a populist, a right-wing populist, and a conservative. Bukele himself has received support from conservatives abroad in both Latin America and the United States, particularly for his anti-crime policies, as well as criticism for democratic backsliding and consolidating power.
Sources: en.wikipedia.org
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.
Mass spectrometry is the standard confirmation of molecular mass and acetylation state. Chromatography establishes purity but does not identify the molecule on its own. The two techniques are normally applied together during verification.
No, because the reported value reflects the detection method and wavelength used, which vary between laboratories. A number stated without method details cannot be compared directly with another supplier's figure. Requesting the chromatogram and the method conditions is a common way to interpret it.
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.